Log in

NASDAQ:LXRXLexicon Pharmaceuticals Stock Price, Forecast & News

$1.91
-0.03 (-1.55 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.90
Now: $1.91
$1.99
50-Day Range
$1.85
MA: $1.97
$2.19
52-Week Range
$1.13
Now: $1.91
$6.49
Volume582,916 shs
Average Volume947,484 shs
Market Capitalization$204.31 million
P/E Ratio3.08
Dividend YieldN/A
Beta1.16
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Read More
Lexicon Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LXRX
Previous SymbolNASDAQ:LEXG
CUSIP52887210
Phone281-863-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$322.07 million
Cash Flow$1.72 per share
Book Value$1.10 per share

Profitability

Net Income$130.13 million

Miscellaneous

Employees202
Market Cap$204.31 million
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

How has Lexicon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LXRX shares have decreased by 15.9% and is now trading at $1.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Lexicon Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Lexicon Pharmaceuticals.

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Lexicon Pharmaceuticals.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its earnings results on Monday, April, 27th. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.06. The biopharmaceutical company earned $8 million during the quarter, compared to the consensus estimate of $7.18 million. Lexicon Pharmaceuticals had a net margin of 26.59% and a return on equity of 125.61%. View Lexicon Pharmaceuticals' earnings history.

What price target have analysts set for LXRX?

6 Wall Street analysts have issued 12 month price objectives for Lexicon Pharmaceuticals' shares. Their forecasts range from $2.10 to $9.00. On average, they anticipate Lexicon Pharmaceuticals' stock price to reach $4.53 in the next year. This suggests a possible upside of 136.9% from the stock's current price. View analysts' price targets for Lexicon Pharmaceuticals.

Has Lexicon Pharmaceuticals been receiving favorable news coverage?

Headlines about LXRX stock have trended negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Lexicon Pharmaceuticals.

Are investors shorting Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 10,920,000 shares, an increase of 8.5% from the June 15th total of 10,060,000 shares. Based on an average daily trading volume, of 929,400 shares, the days-to-cover ratio is currently 11.7 days. Approximately 10.6% of the company's stock are sold short. View Lexicon Pharmaceuticals' Current Options Chain.

Who are some of Lexicon Pharmaceuticals' key competitors?

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the following people:
  • Mr. Lonnel Coats, Pres, CEO & Director (Age 54)
  • Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 54)
  • Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 56)
  • Dr. Praveen Tyle, Exec. VP of R&D (Age 59)
  • Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 60)

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $1.91.

How big of a company is Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals has a market capitalization of $204.31 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.

What is Lexicon Pharmaceuticals' official website?

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.